Management Policies
Message from Leadership
Net sales, operating profit, and profit attributable to owners of the parent all reached record highs.
Net sales surpassed ¥500 billion, buoyed by growth in all regions.
Operating profit posted double-digit growth, driven by higher gross profit on increased sales.
May. 2025
Kaoru Asano
President
President
In the fiscal year ended March 31, 2025, the Sysmex Group achieved strong results across all regions. Growth was driven by a favorable global rollout of the XR™ -Series in the hematology field *¹ and continued success in capturing growth opportunities in emerging markets. Operating profit rose by double digits, supported by an increase in gross profit on higher sales, effective effort to control SG&A expenses, and the positive impact of yen depreciation.
Net sales rose 10.2% year on year, operating profit increased 11.7%, and profit attributable to owners of the parent rose 8.1%—all of which marked record highs.
By segment, the diagnostics business generated sales growth across all fields. In particular, the hematology field saw strong performance, as the XR-Series was introduced to markets globally, including Japan and the EMEA region.
Business in the hemostasis field also expanded steadily, supported by the positive effects of direct sales in the Americas and EMEA.
In the medical robotics business, we made steady inroads in the Asia Pacific market. In the fiscal year ended March 31, 2025, the number of systems installed globally grew to 89, with the number of surgeries performed reaching 9,400, and this number continues to rise. We are actively expanding this business beyond Japan to overseas markets.
In the fiscal year ending March 31, 2026, we will accelerate expansion in emerging markets, including the launch of operations at a new factory in India capable of producing both instruments and reagents. For the year, we forecast net sales of ¥535.0 billion, operating profit of ¥91.5 billion, and profit attributable to owners of the parent of ¥57.0 billion—all marking another year of record-high performance. *²
We also plan to increase the annual dividend by ¥2 per share, bringing the total to ¥32 per share.
We sincerely thank all our stakeholders for your continued support and encouragement.
*1 Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.
*2 Assumed exchange rates: USD1.00=JPY142.0, EUR1.00=JPY160.0, CNY1.00=JPY19.5
- For more information please see the materials below.
- Financial Reports & Presentations